日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Mutant p53 epigenetically rewires CXCL10 to promote CD8⁺ T-cell infiltration and enhance the anti-PD-1 response in advanced prostate cancer

突变型p53通过表观遗传机制重塑CXCL10,促进CD8⁺ T细胞浸润,并增强晚期前列腺癌中的抗PD-1反应。

Chen, Jia; Ge, Qintao; He, Jun; Bian, Zichen; Yu, Haoming; Li, Chun; Meng, Jialin; Yin, Shuiping; Hao, Zongyao; Liang, Chaozhao; Zhang, Meng

In silico validation of a new classifier, PCSCG(ier) , for predicting recurrence-free survival in prostate cancer patients: Evidence from multiple datasets

利用计算机模拟方法验证一种新的分类器 PCSCG(ier),用于预测前列腺癌患者的无复发生存期:来自多个数据集的证据

Zhang, Meng; Bian, Zichen; Chen, Jia; Chen, Lei; Zhou, Jun; Niu, Qingsong; Hao, Zongyao; Meng, Jialin; Liang, Chaozhao

Landscape of the intratumroal microenvironment in bladder cancer: Implications for prognosis and immunotherapy

膀胱癌肿瘤内微环境图谱:对预后和免疫治疗的意义

Bian, Zichen; Chen, Jia; Liu, Chang; Ge, Qintao; Zhang, Meng; Meng, Jialin; Liang, Chaozhao

Establishment of a five-enzalutamide-resistance-related-gene-based classifier for recurrence-free survival predicting of prostate cancer.

建立基于五种恩扎卢胺耐药相关基因的分类器,用于预测前列腺癌的无复发生存期

Chen Jing, Meng Jialin, Liu Yi, Bian Zichen, Niu Qingsong, Chen Junyi, Zhou Jun, Zhang Li, Zhang Meng, Liang Chaozhao

Fifteen-MiRNA-Based Signature Is a Reliable Prognosis-Predicting Tool for Prostate Cancer Patients

基于15种miRNA的特征谱是前列腺癌患者可靠的预后预测工具

Bian, Zichen; Huang, Xinbo; Chen, Yiding; Meng, Jialin; Feng, Xingliang; Zhang, Meng; Zhang, Li; Zhou, Jun; Liang, Chaozhao

Prognostic Role of Prothrombin Time Activity, Prothrombin Time, Albumin/Globulin Ratio, Platelets, Sex, and Fibrinogen in Predicting Recurrence-Free Survival Time of Renal Cancer

凝血酶原时间活性、凝血酶原时间、白蛋白/球蛋白比值、血小板、性别和纤维蛋白原在预测肾癌无复发生存期中的预后作用

Bian, Zichen; Meng, Jialin; Niu, Qingsong; Jin, Xiaoyan; Wang, Jinian; Feng, Xingliang; Che, Hong; Zhou, Jun; Zhang, Li; Zhang, Meng; Liang, Chaozhao